James R. Hagman
Professor
Department of Biomedical Research
  • 5280 Top Doctors 2016
  • Recognized as a 5280 Top Doctor
  • America’s Top Doctors 2015 — Castle Connolly, Medical, Ltd.
  • Recognized in America’s Top Doctors — Castle Connolly, Inc.
  • Best Doctors in America® 2015 — Best Doctors, Inc.
  • Recognized in Best Doctors in America® — Best Doctors, Inc.
  • America’s Top Doctors 2016 — Castle Connolly Medical, Ltd.
  • Research AreasResearch Areas
    • Antibodies
    • B Cells
    • Epigenetics
    • Gene Expression
    • Leukemia/Lymphoma

    Special Interests

    Research Interests

    Regulation of B cell transcription and development Lymphocyte differentiation proceeds through multiple stages characterized by the expression of distinct sets of genes. My laboratory’s goals include understanding how the nuclear proteins Early B cell Factor (EBF) and Pax5 (B cell-specific activator protein) regulate B lineage specification, commitment and the immune response to antigens. EBF has been identified as a crucial factor for lineage determination. EBF regulates many genes (such as mb-1) involved in assembly of the pre-B and mature B cell receptors for antigen (pre-BCR and BCR). We recently identified EBF as an early mediator of changes in mb-1 gene chromatin structure, including DNA demethylation and enhanced accessibility. Pax5 acts downstream of EBF as an important regulator of the early B cell-specific transcriptome, but is also important at later stages of B cell maturation. Notably, Pax5 is a key factor for establishing B cell lineage commitment. To better understand how these proteins function in B cells, my lab employs a combination of biochemical and genetic methods, including transgenic and gene targeted mice. Ultimately, we wish to understand how regulatory signals are integrated for activation and/or repression of genes that contribute to normal immunity, immune diseases, and cancer.

    Education

    Education
    University of Washington, Seattle, PhD, Microbiology
    University of Washington, Seattle, MS, Microbiology
    University of California, Berkeley, BA, Genetics
    Residency
    Howard Hughes Medical Institute, Postdoctoral
    University of California, San Francisco, Postdoctoral

    Awards & Recognition

    2009-2013: Member, NIH CMI-B Study Section
    2006-2011: Editorial Board, Journal of Biological Chemistry
    2008-Present: Advisory Board, Faculty of 1000 Biology
    2008: Ad hoc Member, NIH Special Emphasis Panel/Scientific Review Group ZRG1 IMM-J (02)
    2007: Research Award, Rocky Mountain Chapter of the Arthritis Foundation
    2007: Co-editor, Current Opinion in Immunology, Lymphocyte Development 2000-2001,
    2006-2007: Scientific Advisory Board Member, Cancer League of Colorado
    2005: Outstanding Scientific Achievement Award, National Jewish Health
    1997-2005: Ad hoc Member, NIH Special Emphasis Panel ZRG IMB 01
    1997-2001: Peer Review Committee on Development, Differentiation and Cancer, Regular Member, American Cancer Society
    1997: Harmon Foundation Award for Arthritis Research
    7/1990-6/1993: Fellow of the Leukemia Society of America

    Professional Memberships

    The Epigenetics Society
    American Society for Biochemistry and Molecular Biology
    Member, American Society of Microbiology
    Member, American Association of Immunologists
    Member, American Association for Cancer Research

    Publications

    Lukin, K, S Fields, L Guerrettaz, D Straign, V Rodriguez, S Zandi, R Månsson, JC Cambier, M Sigvardsson and J Hagman. 2011. A dose-dependent role for EBF1 in repressing non-B cell specific genes. Eur J Immunol, 41:1787-1793 (PMCID: PMC3127254).
     
    Musselman, CA, J Ramirez, JK Sims, RE Mansfield, SS Oliver, JM Denu, JP Mackay, PA Wade, J Hagman and TG Kutateladze. 2012. Bivalent recognition of nucleosomes by the tandem PHD fingers of CHD4 is required for CHD4-mediated repression. Proc Natl Acad Sci USA, 109:787-792 (PMCID: PMC3271909).
     
    Hagman, J, J Ramírez and K Lukin. 2012. B lymphocyte lineage specification, commitment and epigenetic control of transcription by Early B cell Factor 1. Curr Topics Micro Immunol, 356:17-38 (PMID: 21735360).
     
    Dege, C, and J Hagman. 2012. Activation of Aicda gene transcription by Pax5 in plasmacytoma cells. Immunol Res, [Epub ahead of print] (PMID: 22956488).
     
    Ramirez, J, C Dege, KG Kutateladze and J Hagman. 2012. MBD2 and multiple domains of CHD4 are required for transcriptional repression by Mi-2/NuRD complexes. Mol Cell Biol, [Epub ahead of print] (PMID: 23071088).

    Academic Affiliations

    University Page for Dr. Hagman

    Contact Information

    • Office: 877.225.5654
    • Fax: 303.398.1396

     

    Locations

    • National Jewish Health Main Campus
      1400 Jackson St.
      Denver, CO 80206

    Patient Ratings

    The Patient Rating score is an average of all responses to care provider related questions on our independent rating system, the Press Ganey Patient Satisfaction Survey.

    Responses are measured on a scale of 1 to 5, with 5 being the best score. Learn more about our patient satisfaction survey.
     
     

    Comments

    Comments are collected in our Press Ganey Patient Satisfaction Surveys. Patients are de-identified to protect confidentiality and patient privacy. Learn more about our patient satisfaction survey.